Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fentanyl. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 9/20 | 0.98 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.98 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.98 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.98 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.98 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
| ▸ | DRD2 | P14416 | 1/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.98 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.98 |
| ▸ | MAOA | P21397 | 1/20 | 0.98 |
| ▸ | DRD4 | P21917 | 1/20 | 0.98 |
| ▸ | MAOB | P27338 | 1/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.98 |
| ▸ | HRH1 | P35367 | 1/20 | 0.98 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.98 |
| ▸ | DRD3 | P35462 | 1/20 | 0.98 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fentanyl SCHEMBL8804 | 0.99 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL916599 | 0.99 | OPRM1 (1.00) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL4321837 | 0.98 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL28383546 | 0.98 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL4326756 | 0.98 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL18249370 | 0.98 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL4971300 | 0.98 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL4353786 | 0.98 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL22637301 | 0.98 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 | |
| Fentanyl SCHEMBL242876 | 0.98 | OPRM1 (0.98) | OPRM1OPRD1OPRK1SIGMAR1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180273475-A1 | HYDROPHILIC FENTANYL DERIVATIVES | ALLEGHENY-SINGER RESEARCH INSTITUTE | 2018-09-27 | — | — | US | claimed |
| WO-2017041095-A1 | HYDROPHILIC FENTANYL DERIVATIVES | ALLEGHENY-SINGER RESEARCH INSTITUTE (US) | 2017-03-09 | — | — | WO | claimed |
| CN-117838375-A | Stent assembly and method of making a stent assembly | 南洋理工大学 | 2024-04-09 | — | — | CN | disclosed |
| US-20090264855-A1 | Method and Device for Transdermal Electrotransport Delivery of Fentanyl and Sufentanil | ALZA CORPORATION (US) | 2009-10-22 | — | — | US | disclosed |
| US-20050171464-A1 | Method and device for transdermal electrotransport delivery of fentanyl and sufentanil | ALZA CORPORATION | 2005-08-04 | — | — | US | disclosed |
| US-20050131337-A1 | Method and device for transdermal delivery of fentanyl and sufentanil | ALZA CORPORATION | 2005-06-16 | — | — | US | disclosed |
| US-6881208-B1 | Method and device for transdermal electrotransport delivery of fentanyl and sufentanil | ALZA CORPORATION | 2005-04-19 | — | — | US | disclosed |
| CN-1118308-C | Device for transdermal electrotransport delivery of fentanyl and sufentanil | ALZA CORP (US) | 2003-08-20 | — | — | CN | disclosed |
| US-6171294-B1 | Method and device for transdermal electrotransport delivery of fentanyl and sufentanil | ALZA CORPORATION | 2001-01-09 | — | — | US | disclosed |
| CN-1187142-A | Device for transdermal electrotransport delivery of fentanyl and sufentanil | ALZA CORP (US) | 1998-07-08 | — | — | CN | disclosed |
| WO-1996039224-A1 | DEVICE FOR TRANSDERMAL ELECTROTRANSPORT DELIVERY OF FENTANYL AND SUFENTANIL | ALZA CORPORATION (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273475-A1 | HYDROPHILIC FENTANYL DERIVATIVES | OPRD1, OPRK1, OGFR | OPRM1 4/4885OPRD1 1/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.